| Spheramine Titan/Schering. | |
| | |
MedLine Citation:
|
PMID: 16044669 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Spheramine, which is composed of microcarriers coated with dopamine-producing human retinal pigment epithelial cells, is being developed by Titan and Schering for the potential treatment of advanced Parkinson's disease. Phase II trials were ongoing in March 2005 and, at this time, were expected to be completed in the second half of 2006. |
| | |
Authors:
|
Donald Grosset; Katherine Grosset |
Related Documents
:
|
22437099 - Scorpion sting pain: which way to treat? 4055839 - A comparison of different methods used to diagnose pseudarthrosis following posterior s... 22191659 - Prehospital burn management in a combat zone. 22296289 - 'i can't see any reason for stopping doing anything, but i might have to do it differen... 22826679 - Pain management - the challenge. 18382309 - L-dopa-induced dyskinesia and stereotactic surgery for parkinson's disease. 16754839 - Neural correlates of antinociception in borderline personality disorder. 2006599 - Treatment of neck and shoulder pain in whip-lash syndrome patients with intracutaneous ... 18958309 - Chronic pain and fatigue: associations with religion and spirituality. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current opinion in investigational drugs (London, England : 2000) Volume: 6 ISSN: 1472-4472 ISO Abbreviation: Curr Opin Investig Drugs Publication Date: 2005 Jul |
Date Detail:
|
Created Date: 2005-07-27 Completed Date: 2006-04-18 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100965718 Medline TA: Curr Opin Investig Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 722-8 Citation Subset: IM |
Affiliation:
|
Southern General Hospital, Department of Neurology, Institute of Neurological Sciences, 1345 Govan Road, Glasgow G51 4TF, UK. d.grosset@clinmed.gla.ac.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Clinical Trials, Phase II as Topic Dopamine / chemistry, metabolism*, therapeutic use Drug Carriers Humans Parkinson Disease / therapy Pigment Epithelium of Eye / chemistry, metabolism* Technology, Pharmaceutical / methods, trends Tissue Therapy / methods*, trends |
| Chemical | |
Reg. No./Substance:
|
0/Drug Carriers |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Drug treatments for subjective tinnitus: serendipitous discovery versus rational drug design.
Next Document: Phenserine Axonyx.